Warning: CMEcorner.com will not work properly with JavaScript disabled! Please enable javascript before proceeding.
Warning: CMEcorner.com will not work properly with JavaScript disabled! Please enable javascript before proceeding.
Start the program at
the bottom of this page
Atrial Fibrillation: Challenges and Opportunities for the Consultant Pharmacist
Release Date: November 18, 2009
Credit Expiration Date: January 4, 2011
UAN: 203-999-09-102-H01-P
Jointly Sponsored by the American Society of Consultant Pharmacists and Medical Communications Media, Inc.
This educational activity is designed for consultant pharmacists who care for older adults with atrial fibrillation in long-term care and U.S. Department of Veterans Affairs (VA) settings.
Pharmacists: 1.5 Contact Hours (0.15 CEU)
Online Presentation
NOTE: This activity was presented on November 18, 2009, in conjunction with ASCP's 40th Annual Meeting and Exhibition.
Participants who received credit for attending either the live presentation or participating in the webcast on that date are not eligible to receive credit for this online activity.
AF continues to be a major health problem in the United States. Approximately 2.2 million people in the United States have been diagnosed with atrial fibrillation (AF), the most common heart rhythm abnormality. The prevalence of AF increases with age, affecting 3.8% of adults over 60 years of age and 9.0% of adults over 80 years of age. AF leads to serious health consequences and significantly reduces quality of life. Specifically, AF increases the risk for stroke by 4- to 5-fold, doubles the risk for dementia, triples the risk for heart failure, and increases the risk for overall mortality by 40% to 90%. Because the prevalence increases with age, the number of people with AF is expected to increase dramatically, from 2 to 5 million in 2000 to 6 to 12 million by 2050. Hospitalizations for AF have increased substantially in the U.S. over the past two decades, contributing to the significant health burden of AF. This certified continuing pharmacy education symposium will focus on challenges consultant pharmacists are likely to face in overcoming barriers to optimal management of AF to reduce the serious health consequences of AF.
Upon completion of this application-based educational activity, the participant should be able to:
1.
Implement strategies to identify patients/residents with atrial fibrillation to facilitate timely and accurate diagnosis.
2.
Assess individual patient risk of developing AF and individual risk of experiencing negative health consequences from AF.
3.
Compare and contrast pharmacologic agents, identifying critical differences between drug classes and agents that can impact individual patient outcomes.
4.
Determine the consultant pharmacist’s role in tailoring treatment plans for individuals with AF.
Robert Lee Page II, PharmD, FCCP, FAHA, BCPS, CGP
Associate Professor, Department of Clinical Pharmacy
Associate Professor, Department of Physical Medicine/Rehabilitation
University of Colorado School of Pharmacy
Aurora, Colorado
Steven Rothman, MD, FACC
Associate Professor of Medicine
Temple University
Campus Chief, Cardiovascular Diseases
Lankenau Hospital, MLH Heart Center
Wynnewood, PA
In accordance with the standards set forth by the Accreditation Council for Pharmacy Education, it is the policy of the American Society of Consultant Pharmacists to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any relevant financial relationship or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with a relevant financial relationship or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker¹s interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Robert Lee Page II, PharmD, FCCP, FAHA, BCPS, CGP, has no relevant financial relationships to disclose.
Steven Rothman, MD, FACC, discloses that he is on the speakers' bureau for AstraZeneca and a consultant to sanofi-aventis.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity, ACPE Universal Activity # 203-999-09-102-H01-P, has been assigned 1.5 Contact Hours (0.15 CEUs).
Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit. Credit will be awarded for a score of 70% or better, and a statement may be printed immediately after passing the post-test.
There is no fee to participate in this educational activity.
Supported through an educational grant from sanofi-aventis U.S.
$0.00
By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.
